ANGLE, the London-listed liquid biopsy company specialising in innovative circulating tumor cell (CTC) diagnostic solutions, continued to surge higher on Wednesday after inking a significant deal with global pharmaceutical giant Eisai Inc yesterday.
ANGLE shares were 12% higher at the time of writing on Wednesday.
In a groundbreaking pilot study valued at $250,000, ANGLE is set to provide CTC analysis using its cutting-edge Portrait HER2 assay. The focus of this study is to evaluate the HER2 (human epidermal growth factor receptor 2) status of breast cancer patients participating in a Phase II trial of the HER2 targeting antibody-drug conjugate (ADC) BB-1701.
The success of this pilot study holds the potential for numerous large-scale follow-up investigations, marking a potentially pivotal moment in cancer research and drug development.
ANGLE’s Portrait HER2 assay stands out for its ability to quantitatively assess both HER2 protein expression (via IF) and HER2/neu gene amplification (via FISH).
This dual-pronged approach is crucial in identifying breast cancer patients who could benefit from anti-HER2 ADC treatment. Notably, HER2-low breast cancer, comprising 55% of all breast cancer cases, represents a significant portion of the market.
Analysts predict that the global HER2+ breast cancer ADC market is poised to reach a staggering US $3.3 billion per annum by 2030. With the market expanding into HER2-low patients, ANGLE’s strategic move to develop a quantitative HER2 assay becomes even more pivotal. This assay allows for the precise stratification of patient populations throughout the treatment pathway, considering that HER2 status can dynamically change over time.
